Advanced Solid Tumor, Non-Hodgkin Lymphoma
Conditions
Keywords
AXT-1003, EZH2, Phase I, Advanced malignancies
Brief summary
This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
Detailed description
AXT1003-1102 is a multicenter, open-label, Phase I safety study of AXT-1003 in patients with advanced malignancies. It is designed to observe the safety of AXT-1003 in patients with advanced malignancies, determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), evaluate the pharmacokinetic profile, and explore the preliminary antitumor activity.
Interventions
DRUGAXT-1003
AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Sponsors
Axter Therapeutics (Beijing) Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. For Ia dose escalation part only: R/R NHL: Locally histopathological diagnosis of relapsed/refractory non-Hodgkin lymphoma (R/R NHL), who have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies. Advanced solid tumors: Locally histopathological diagnosis of locally advanced unresectable and metastatic solid tumors,The above subjects have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies. For Ib dose expansion part only: Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) 2. Eastern Cooperative Oncology Group (ECOG) performance status scale 0 to 1. 3. Have a life expectancy of at least 3 months. 4. For Ib dose expansion part and not mandatory for Ia dose escalation part: Subjects with R/R NHL must have measurable lesions as defined by Lugano 2014 criteria. Subjects with advanced solid tumors must have measurable or evaluable lesions as defined by RECIST 1.1. 5. Adequate organ and bone marrow functions. 6. The adequate washout period for prior therapy . 7. Subjects must use a highly effective contraception method throughout the study and for 3 months after discontinuation of the study drug. 8. Signed ICF and willing to comply with all the requirements in the protocol.
Exclusion criteria
1. Diagnosis of precursor B-cell lymphoblastic leukemia/lymphoma, precursor T-cell lymphoblastic leukemia/lymphoma, precursor NK cell lymphoblastic leukemia/lymphoma. Diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). 2. Central nervous system infiltration. 3. Uncontrolled or significant cardiovascular disease. 4. Major surgery within 4 weeks before the first dose of study drug. 5. Known or suspected hypersensitivity to AXT-1003 or any of the excipients. 6. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of AXT-1003. 7. History of other malignancies prior to enrollment; except for subjects with basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or other carcinomas in situ who have undergone possible curative treatment and do not have disease recurrence within 5 years since starting the treatment. 8. Any prior treatment-related clinically significant toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment. 9. Active infection requiring systemic treatment. 10. Infection with hepatitis B virus with positive hepatitis B surface antigen, or hepatitis C virus with detectable anti-hepatitis C circulating viral RNA. 11. Subjects known to be infected with human immunodeficiency virus and active tuberculosis. 12. Females who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicity (DLT) (Dose Escalation) | Up to 28 days | Dose Escalation only: to characterize the dose limiting toxicities (DLTs) of AXT-1003. |
| Number of Participants with Adverse Events (AEs) | Baseline up to 30 days after the last dose of study | Laboratory test ,ECG, vital signs, physical examination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rates (ORR) | Up to 3 years | ORR is defined as the proportion of subjects with a CR or PR. |
| Duration of response(DOR) | Up to 3 years | DOR is defined as the time from the initial objective response to progression of disease (PD) or death after the response, whichever occurs first. |
| Progression free survival (PFS) | Up to 3 years | Progression-free survival is defined as the time from the first dose of study treatment to the first PD or death for any reason in the absence of documented PD, whichever occurs first. |
| Time to response (TTR) | Up to 3 years | Time to response is defined as the time from first dose of study treatment to the first objective tumor response. |
| Disease control rate (DCR) | Up to 3 years | Disease control rate is defined as the proportion of subjects with a CR, PR, or stable disease(SD). |
| Maximum observed concentration (Cmax) of AXT-1003 | Up to 15 days | Pharmacokinetics of AXT-1003 |
| Time of maximum observed concentration (tmax) of AXT-1003 | Up to 15 days | Pharmacokinetics of AXT-1003 |
| Area under the curve from the time of dosing to the time of the last measurable concentration (AUCtau) of AXT-1003 | Up to 15 days | Pharmacokinetics of AXT-1003 |
| Minimum observed concentration (Cmin) of AXT-1003 | Up to 15 days | Pharmacokinetics of AXT-1003 |
| Terminal elimination half-life (t1/2) of AXT-1003 | Up to 15 days | Pharmacokinetics of AXT-1003 |
| Total body clearance (CL/F) of AXT-1003 | Up to 15 days | Pharmacokinetics of AXT-1003 |
Countries
China
Contacts
CONTACTWilson Wang
STUDY_DIRECTORQian Gao
Axter Therapeutics (Beijing) Co., Ltd
Outcome results
None listed